Mn Services Vermogensbeheer B.V. Sells 500 Shares of Becton, Dickinson and Company (NYSE:BDX)

Mn Services Vermogensbeheer B.V. reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 0.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 116,604 shares of the medical instruments supplier’s stock after selling 500 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Becton, Dickinson and Company were worth $27,252,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Becton, Dickinson and Company by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 26,123,450 shares of the medical instruments supplier’s stock worth $6,369,681,000 after buying an additional 195,931 shares during the period. Bank of New York Mellon Corp increased its position in Becton, Dickinson and Company by 4.4% in the 1st quarter. Bank of New York Mellon Corp now owns 4,065,443 shares of the medical instruments supplier’s stock worth $1,005,994,000 after buying an additional 172,005 shares during the period. Clearbridge Investments LLC increased its position in Becton, Dickinson and Company by 0.6% in the 4th quarter. Clearbridge Investments LLC now owns 3,154,438 shares of the medical instruments supplier’s stock worth $769,147,000 after buying an additional 19,200 shares during the period. Norges Bank bought a new position in Becton, Dickinson and Company in the 4th quarter worth approximately $761,798,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Becton, Dickinson and Company by 4.3% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,539,663 shares of the medical instruments supplier’s stock valued at $628,440,000 after purchasing an additional 105,821 shares during the period. 86.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on BDX shares. Stifel Nicolaus boosted their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. The Goldman Sachs Group started coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 price objective on the stock. Barclays boosted their price objective on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Raymond James lowered their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Finally, Evercore ISI lowered their price objective on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $279.50.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the transaction, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX stock traded up $1.08 during trading on Friday, hitting $236.38. The company had a trading volume of 822,086 shares, compared to its average volume of 1,433,813. The company has a fifty day moving average price of $233.26 and a two-hundred day moving average price of $236.10. The company has a current ratio of 1.85, a quick ratio of 0.97 and a debt-to-equity ratio of 0.70. The company has a market cap of $68.32 billion, a P/E ratio of 52.07, a P/E/G ratio of 2.06 and a beta of 0.42. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $283.50.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.96 earnings per share. Equities research analysts expect that Becton, Dickinson and Company will post 13.06 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 1.61%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.